Acebutolol: Ten years of experience

https://doi.org/10.1016/0002-8703(85)90712-4Get rights and content

Abstract

During 10 years of clinical use involving almost 3 million patient-years acebutolol has become established as a remarkably safe and well-tolerated beta-blocking agent, effective in treating essential hypertension and cardiac arrhythmias. The existence of a long-lived active metabolite (diacetolol) confers a 24-hour duration of action, which permits effective use of a once-daily regimen, particularly for hypertension. Acebutolol has low lipid solubility and low protein binding; the former property reduces the risk of central side effects, and the latter means that displacement interactions with other drugs are unlikely. Because acebutolol and its metabolite normally have both renal and hepatic excretion pathways, an alternative pathway is available should either be compromised through disease. Acebutolol is cardioselective, and clinical use has borne out the low incidence of bronchospasm in patients with impaired lung function. The possession of intrinsic sympathomimetic activity (ISA) leads to only modest reductions in cardiac output, which in turn reduces the chance of excessive bradycardia and the likelihood of precipitating heart failure. A combination of selectivity and ISA may be responsible for the low incidence of tiredness and cold extremities observed with acebutolol compared with other beta blockers. The unique pharmacologic and pharmacokinetic profile of acebutolol confers several therapeutic advantages and may be responsible for the generally low level of side effects experienced in clinical use.

References (181)

  • PB Woods et al.

    An investigation of the comparative liposolubilities of beta-adrenoceptor blocking agents

    J Pharm Pharmacol

    (1981)
  • JA Street et al.

    Lung accumulation of some beta-adrenoceptor antagonists

    J Pharm Pharmacol

    (1978)
  • MD Day et al.

    The central uptake of beta-adrenoceptor antagonists

    J Pharm Pharmacol

    (1977)
  • TJ Coombs et al.

    Blood plasma binding of acebutolol and diacetolol in man

    Br J Clin Pharmacol

    (1980)
  • R Zaman et al.

    The penetration of acebutolol and its major metabolite, diacetolol, into human cerebrospinal fluid and saliva

    Br J Clin Pharmacol

    (1981)
  • PJ Meffin et al.

    Quantitation in plasma and urine of acebutolol and a major metabolite with preliminary observations on their disposition

    Res Commun Chem Pathol Pharmacol

    (1976)
  • DG Ferry et al.

    High-performance liquid chromatographic analysis of acebutolol and its major metabolites

  • R Gabriel et al.

    Preliminary observations on the excretion of acebutolol and its acetyl metabolite in the urine and faeces of man

    J Pharm Pharmacol

    (1981)
  • JE Holt et al.

    Use of reversed-phase high-pressure liquid chromatography for the assay of acebutolol, practolol and propranolol in plasma

    Br J Clin Pharmacol

    (1981)
  • MA Lefebvre et al.

    Beta-blocking agents: Determinations of biological levels using high-performance liquid chromatography

    J Liquid Chromatogr

    (1981)
  • AR Boobis et al.

    Chromatographic resolution and stereoselective disposition of acebutolol and diacetolol in dog and man

    Br J Pharmacol

    (1984)
  • MG Sankey et al.

    Preliminary study of the disposition in man of acebutolol and its metabolite, diacetolol, using a new stereoselective HPLC method

    J Pharm Pharmacol

    (1984)
  • D Heusse et al.

    Les espèces animales et le métabolisme

    Inserm

    (1980)
  • DR Maxwell et al.

    Acebutolol (“Sectral”). I. Review of the pharmacology and pharmacokinetics

    Clin Trials J

    (1974)
  • BD Andresen et al.

    Metabolism of acebutolol-d6 in the rat correlates with the identification of a new metabolite in human urine

    Drug Metab Dispos

    (1979)
  • MS Alexander et al.

    Acebutolol metabolism in the isolated perfused rat liver

    Clin Pharmacol Ther

    (1982)
  • A Gulaid et al.

    Lack of correlation between acetylator status and the production of the acetyl metabolite of acebutolol in man

    Br J Clin Pharmacol

    (1978)
  • PJ Meffin et al.

    Acebutolol disposition after intravenous administration

    Clin Pharmacol Ther

    (1977)
  • PJ Meffin et al.

    Dose-dependent acebutolol disposition following oral administration

    Clin Pharmacol Ther

    (1978)
  • RA Winkle et al.

    Acebutolol metabolite plasma concentrations during chronic oral therapy

    Br J Clin Pharmacol

    (1977)
  • A Roux et al.

    Pharmacokinetics of acebutolol after intravenous bolus administration

    Br J Clin Pharmacol

    (1980)
  • A Roux et al.

    Systemic bioavailability of acebutolol in man

    Biopharm Drug Dispos

    (1983)
  • A Gulaid et al.

    The pharmacokinetics of acebutolol in man, following the oral administration of acebutolol HCl as a single dose (400 mg), and during and after repeated oral dosing (400 mg b.d.)

    Biopharm Drug Dispos

    (1981)
  • CM Kaye et al.

    The biliary excretion of acebutolol in man

    J Pharm Pharmacol

    (1976)
  • CM Kaye et al.

    Observations on the pharmacokinetics of acebutolol

    Clin Pharmacol Ther

    (1976)
  • JA Street et al.

    Tissue levels of several radiolabeled beta-adrenoceptor antagonists after intravenous administration in rats

    Arch Int Pharmacodyn

    (1979)
  • S Sakurai et al.

    Metabolic fate of acebutolol

    Iyakuhin Kenkyu

    (1978)
  • G Bianchetti et al.

    Placental transfer and pharmacokinetics of acebutolol in newborn infants

    Clin Pharmacol Ther

    (1981)
  • F Daffos et al.

    Passage transplancentaire de l'acébutolol et du diacetolol

    Nouv Presse Med

    (1982)
  • JP Tillement et al.

    Le lait, compartiment de diffusion d'un médicament

    Therapie

    (1982)
  • CM Kaye et al.

    Plasma-salivary ratios of acebutolol and propranolol

    Br J Clin Pharmacol

    (1977)
  • JF Giudicelli et al.

    Acebutolol saliva excretion

    Br J Clin Pharmacol

    (1979)
  • A Roux et al.

    Pharmacokinetics of acebutolol in patients with all grades of renal failure

    Eur J Clin Pharmacol

    (1980)
  • RF Collins et al.

    Studies on the disposition and fate of [14C]-acebutolol in man and dog

    Br J Clin Pharmacol

    (1976)
  • CF George et al.

    Elimination of drugs by active intestinal transport

    J Pharm Pharmacol

    (1979)
  • MS Alexander et al.

    Acebutolol kinetics following oral and intravenous administration in man

    Clin Pharmacol Ther

    (1984)
  • SH Wan et al.

    Pharmacokinetics, pharmacology of atenolol and effect of renal disease

    Br J Clin Pharmacol

    (1979)
  • J McAinsh et al.

    Atenolol kinetics in renal failure

    Clin Pharmacol Ther

    (1980)
  • WH Frishman

    Beta-adrenoceptor antagonists: New drugs and new indications

    N Engl J Med

    (1981)
  • TB Tjandramaga et al.

    The effect of end-stage renal failure and haemodialysis on the elimination kinetics of sotalol

    Br J Clin Pharmacol

    (1976)
  • Cited by (18)

    • Acebutolol

      1990, Analytical Profiles of Drug Substances and Excipients
    • Stereospecific high-performance liquid chromatographic assay of acebutolol in human plasma and urine

      1990, Journal of Chromatography B: Biomedical Sciences and Applications
    • Hypertension in children

      1988, Current Problems in Pediatrics
    View all citing articles on Scopus
    View full text